Developing Disease Activity and Response Criteria in Connective Tissue Disease-related Interstitial Lung Disease

REFERENCES

1. 1.↵
   1. Tashkin DP,
   2. Elashoff R,
   3. Clements PJ,
   4. Goldin J,
   5. Roth MD,
   6. Furst DE,
   7. et al.

   Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655–66.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Minnock P,
   2. Kirwan J,
   3. Bresnihan B

   . Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis. Rheumatology 2009;48:1533–6.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Distler O,
   2. Behrens F,
   3. Huscher D,
   4. Foeldvari I,
   5. Zink A,
   6. Nash P,
   7. et al.

   Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Rheumatology 2006;45:1455–7.

   OpenUrlFREE Full Text
4. 4.↵
   1. Boers M,
   2. Brooks P,
   3. Strand CV,
   4. Tugwell P

   . The OMERACT filter for outcome measures in rheumatology. J Rheumatol 1998;25:198–9.

   OpenUrlPubMed
5. 5.↵
   1. Huscher D,
   2. Saketkoo LA,
   3. Pittrow D,
   4. Khanna D

   . Development of clinical trial assessments for the study of interstitial lung disease in patients who have connective tissue diseases—methodological considerations. Curr Rheumatol Rep 2010;6:145–50.

   OpenUrlCrossRef
6. 6.↵
   1. Pittrow D,
   2. Ghofrani HA,
   3. Opitz CF,
   4. Huscher D,
   5. Hoeper MM

   . International, prospective register for the documentation of first-line and maintenance therapy in patients with pulmonary hypertension (CompERA-XL). Dtsch Med Wochenschr 2009;134 Suppl 5:S173–5.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Stucki G,
   2. Boonen A,
   3. Tugwell P,
   4. Cieza A,
   5. Boers M

   . The World Health Organisation International Classification of Functioning, Disability and Health: a conceptual model and interface for the OMERACT process. J Rheumatol 2007;34:600–6.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Bottomley A,
   2. Jones D,
   3. Claassens L

   . Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency. Eur J Cancer 2009;45:347–53.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Speight J,
   2. Barendse SM

   . FDA guidance on patient reported outcomes. BMJ 2010;340:c2921.

   OpenUrlFREE Full Text
10. 10.↵
    1. Martinez FJ,
    2. Safrin S,
    3. Weycker D,
    4. Starko KM,
    5. Bradford WZ,
    6. King TE Jr.,
    7. et al;
    8. IPF Study Group

    The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005;142:963–7.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Nannini C,
    2. West CP,
    3. Erwin PJ,
    4. Matteson EL

    . Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2009;11:408.

    OpenUrlPubMed
12. 12.↵
    1. Khanna D,
    2. Brown KK,
    3. Clements PJ,
    4. Elashoff R,
    5. Furst DE,
    6. Goldin J,
    7. et al.

    Systemic sclerosis-associated interstitial lung disease — proposed recommendations for future randomized clinical trials. Clin Exp Rheumatol 2010;28:S55–62.

    OpenUrlPubMed
13. 13.↵
    1. Noth I,
    2. Martinez FJ

    . Recent advances in idiopathic pulmonary fibrosis. Chest 2007;132:637–50.

    OpenUrlCrossRefPubMed